MM patients (n = 60) comprise G3a, with 17 patients treated with anti-CD38; G3b, with 3 patients treated with anti-BCMA; G4, with 20 patients on other therapies [proteasome inhibitors (PI) or immunomodulatory drugs (IMiD) without anti-CD38 or anti-BMCA], and G5, with 20 MM patients off-therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.